stockrow
Friday 6 November 2026
Export KOD’s income statement to Excel — free account
Kodiak Sciences Inc.
- EPS
- −1.94%
- Free cash flow
- −33.9%
Quarter to June 2026, against a year earlier
98.85
7.83
+8.60%
Follow KOD
Alert me
Kodiak Sciences Inc. (KOD) Net income
Kodiak Sciences Inc.'s net income for fiscal 2025 was −$230.0M, compared with −$176.2M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$242.0M. Over the past ten years it has ranged from −$333.8M (fiscal 2022) to −$17.1M (fiscal 2016); the current reading is higher than 40% of that period. Kodiak Sciences Inc. ranks 540th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$230.0M | — |
| FY2024 | −$176.2M | — |
| FY2023 | −$260.5M | — |
| FY2022 | −$333.8M | — |
| FY2021 | −$267.0M | — |
| FY2020 | −$133.1M | — |
| FY2019 | −$47.4M | — |
| FY2018 | −$41.4M | — |
| FY2017 | −$27.9M | — |
| FY2016 | −$17.1M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | −$65.6M | — |
| Mar 2026 | −$58.2M | — |
| Dec 2025 | −$56.7M | — |
| Sep 2025 | −$61.5M | — |
| 33 more quarters | Free account |
Against its own ten years
Low −$333.8M
High −$17.1M
Ten-year median
−$154.7M
Current reading's percentile
40
Net income against peers
| Company | Net income |
|---|---|
| LGND Ligand Pharmaceuticals Incorporated compare | $51.5M |
| BLTE Belite Bio, Inc. Sponsored ADR compare | −$77.6M |
| PTCT PTC Therapeutics, Inc. compare | −$106.0M |
| ORKA Oruka Therapeutics, Inc. compare | −$132.9M |
| CGON CG Oncology, Inc. compare | −$224.4M |
| KOD Kodiak Sciences Inc. | −$242.0M |
| IMVT Immunovant, Inc. compare | −$538.2M |
| IONS Ionis Pharmaceuticals, Inc. compare | −$565.2M |
| MIRM Mirum Pharmaceuticals, Inc. compare | −$903.9M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item